1. Home
  2. BEAM vs BFAM Comparison

BEAM vs BFAM Comparison

Compare BEAM & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$29.02

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Logo Bright Horizons Family Solutions Inc.

BFAM

Bright Horizons Family Solutions Inc.

HOLD

Current Price

$65.03

Market Cap

3.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
BFAM
Founded
2017
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.6B
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
BEAM
BFAM
Price
$29.02
$65.03
Analyst Decision
Buy
Buy
Analyst Count
12
7
Target Price
$50.75
$114.57
AVG Volume (30 Days)
1.8M
1.1M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
82.31
40.00
EPS
N/A
0.62
Revenue
$24,000.00
$1,903,182,000.00
Revenue This Year
N/A
$8.19
Revenue Next Year
$33.77
$5.83
P/E Ratio
N/A
$105.34
Revenue Growth
33.33
N/A
52 Week Low
$15.60
$57.63
52 Week High
$36.44
$130.76

Technical Indicators

Market Signals
Indicator
BEAM
BFAM
Relative Strength Index (RSI) 47.10 46.02
Support Level $26.96 $64.34
Resistance Level $29.06 $104.97
Average True Range (ATR) 2.12 2.78
MACD -0.21 0.79
Stochastic Oscillator 11.71 73.02

Price Performance

Historical Comparison
BEAM
BFAM

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

About BFAM Bright Horizons Family Solutions Inc.

Bright Horizons Family Solutions Inc provider of early education and child care, family care solutions, and workforce education services that help working families and client employees personally and professionally. It provides services under multi-year contracts with employers that offer early education and child care, back-up care, and educational advisory services as part of their employee benefits package. The company has three business segments; Full-service center-based child care, Backup care, and Educational advisory services. The majority of the revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, and Others.

Share on Social Networks: